Abstract
In this update, we explore the vocal adoption of the target trial emulation framework by the US FDA, the FRAME methodology for systematically evaluating the use and impact of RWE in health technology assessment and regulatory submissions, and the Canadian CanREValue framework for incorporating RWE into cancer medicine reassessment decisions.